Drug Profile
NB 02
Alternative Names: DA-9803; NB-02Latest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Dong-A ST
- Developer Dong-A ST; NeuroBo Pharmaceuticals
- Class Antidementias; Neuroprotectants; Nootropics; Phytotherapies
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neurodegenerative disorders
- No development reported Alzheimer's disease
Most Recent Events
- 04 Apr 2023 Preclinical development is still ongoing in Alzheimer's-disease in USA (Neurobo Pharma website, April 2023)
- 30 Mar 2023 NB 02 is available for licensing as of 30 Mar 2023. http://www.neurobopharma.com
- 28 Feb 2023 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA